If there’s a mantra in the ETF space, it might be: If at first you don’t succeed, repackage.
That’s sort of what's happening with the ETFMG Treatments Testing and Advancements ETF (GERM), which launched in 2020 to tap into efforts to fight Covid but has recently shifted its marketing pitch toward monkeypox, which the Biden Administration has declared a public health emergency.
The $29 million fund from the $4.5 billion boutique shop ETF Managers Group is still made up of the same underlying investments that were gathered at the start of the global pandemic but is now trying to catch a ride on whatever momentum is building around efforts to fight monkeypox.
“The broad portfolio is targeting any type of pandemic or virus in society,” said Alex Gordon, director at ETFMG.
Gordon said the idea behind GERM has always been to offer something beyond standard pharmaceutical company exposure, which is why the fund has a 30% crossover with the biotechnology sector, holdings-wise, but only a 14% crossover, weightings-wise.
“We didn’t want to provide a fund dominated by pharma,” he said. “We have some representation to pharma but on a much smaller scale.”
Top weightings in the fund include Laboratory Corp. of America Holdings (LH), Quest Diagnostics (DGX), Moderna (MRNA) and Alnylam Pharmaceuticals (ALNY).
The fund is described as providing exposure to a subsector of the biotech industry, which is generally in line with ETFMG’s subsector strategy.
Other examples of where the ETF provider offers fine-tuned exposure includes the ETFMG Travel Tech ETF (AWAY), ETFMG Prime Security ETF (HACK) and ETFMG Alternative Harvest ETF (MJ).
In terms of performance, GERM, which charges 68 basis points, has been riding the market extremes with a 24% decline so far this year, following a 14% gain last year.
“I would put this more into the growth bucket,” Gordon said. “It has been driven down by the market. But these companies and this entire episode we’ve experienced with Covid are not leaving.”
A state-by-state analysis of retail investor behavior reveals AI-powered research tools are reshaping how clients approach investment decisions.
LPL picks up $1.1B from Wells Fargo's independent channel as the wirehouse gains a $410M family team from UBS.
Most Americans want to age at home but few have a financial plan to pay for it, according to new research.
Halbert Hargrove senior wealth advisor weighs in on the products' guaranteed income upside, the operational drag and his wish list for carriers.
With 8.6% of advisors set to switch firms in 2026, Cerulli says advisor recruitment hinges on technology, branding and HNW support.
Knighthead Life entered the market with a competitive MYGA. A strong launch earned advisor confidence and paved the way for FIAs.
As AI makes financial information more accessible than ever, Lana Hock explains why human judgment, trust, and empathy remain the qualities clients value most in a financial advisor
